Aduhelm (Drug)

January 6, 2023

FDA approves Leqembi, new treatment for early-stage Alzheimer’s

[ad_1] The drug Leqembi may slightly slow cognitive decline in the early stages of the disease, but it comes with some safety risks. However, data suggests it holds more promise than the small number of other treatments available. [ad_2] Source link
December 29, 2022

Congressional investigation into Alzheimer’s drug Aduhelm objects to FDA and Biogen

[ad_1] The report said the FDA’s approval process for Aduhelm was “riddled with irregularities” and criticized Biogen for setting an “unjustifiably high price.” [ad_2] Source link
September 27, 2022

Alzheimer’s drug slows cognitive decline in key study

[ad_1] Biogen and Eisai reported the results of a large, late-stage clinical trial of lecanemab, a drug they are developing. [ad_2] Source link
Alzheimer’s drug slows cognitive decline in key study
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more